Involved in the "first major bidding case of national procurement", ApicHope Pharmaceutical may face its first loss after going public | Interpretations
① Due to the continued increase in research and development investment, reimbursement of medical insurance refunds, and other factors, ApicHope Pharmaceutical may experience its first loss since its listing in 2024. ② It is expected that the net loss in Q4 will be between 0.225 billion yuan and 0.433 billion yuan.
Revenue has "returned to the 10 billion" target achieved. Three Squirrels Inc. expects a net profit increase of over 80% year-on-year last year | Interpretations.
① Three Squirrels Inc. expects to achieve revenue of 10.2 billion to 10.8 billion yuan in 2024, a year-on-year growth of 43.37% to 51.8%; it is expected to achieve net income of 0.4 billion to 0.42 billion yuan, a year-on-year increase of 81.99% to 91.09%; ② Following categories and channels, Three Squirrels Inc. has started to focus on building sub-brands.
Is the sales momentum of Douyin effective? Three Squirrels Inc. is expected to break 10 billion in revenue in 2024.
Channel transformation.
At the CES Technology Spring Festival Gala, there is an explosion of AI companionship products, which are expected to become the fastest-growing AI terminals.
According to media reports, several AI companion products were showcased at this year's CES exhibition. Xinyie Securities' Zhang Lin stated that AI toys, thanks to the significantly enhanced interactive experience, fewer hardware limitations due to non-serious usage scenarios, and lower costs for AI integration, have a solid foundation for application promotion and are expected to become one of the fastest-growing AI terminals.
Musk: The goal this year is to manufacture thousands of Optimus humanoid robots, aiming for a tenfold increase each year over the next two years.
Musk stated that if everything goes smoothly, the production of humanoid robots will increase tenfold by 2026, with the goal of producing between 0.05 million to 0.1 million humanoid robots next year, and then increasing it tenfold again the following year.
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.